|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.74 USD | +1.47% |
|
-2.02% | +12.61% |
| Feb. 11 | Tranche Update on Bristol-Myers Squibb Company's Equity Buyback Plan announced on October 27, 2016. | CI |
| Feb. 09 | AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 6.99B | 6.33B | 8.02B | -8.95B | 7.05B | |||||
Depreciation & Amortization - CF | 557M | 582M | 569M | 575M | 577M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 10.2B | 9.7B | 9.2B | 9B | 3.5B | |||||
Depreciation & Amortization, Total | 10.76B | 10.28B | 9.77B | 9.58B | 4.08B | |||||
(Gain) Loss From Sale Of Asset | -684M | -231M | -22M | -15M | -36M | |||||
(Gain) Loss on Sale of Investments - (CF) | -745M | 801M | 160M | -16M | -280M | |||||
Asset Writedown & Restructuring Costs | 1.21B | 184M | 1.21B | 16.41B | 4.86B | |||||
Stock-Based Compensation (CF) | 583M | 457M | 518M | 507M | 553M | |||||
Other Operating Activities, Total | -654M | -2.52B | -3.89B | -3.14B | -1.62B | |||||
Change In Accounts Receivable | -1.05B | -663M | -995M | 264M | -295M | |||||
Change In Inventories | 13M | -69M | -751M | -486M | -184M | |||||
Change In Accounts Payable | 245M | 109M | 198M | 184M | -2M | |||||
Change in Unearned Revenues | - | - | - | - | - | |||||
Change In Income Taxes | -1.06B | -1.42B | -603M | -1.26B | -4M | |||||
Change in Other Net Operating Assets | 606M | -183M | 237M | 2.11B | 30M | |||||
Cash from Operations | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B | |||||
Capital Expenditure | -973M | -1.12B | -1.21B | -1.25B | -1.31B | |||||
Cash Acquisitions | -1.61B | -4.29B | -1.17B | -21.82B | -3.94B | |||||
Divestitures | 748M | 1.3B | 909M | 1.1B | 1.07B | |||||
Investment in Marketable and Equity Securities, Total | 1.3B | 3.04B | -826M | 618M | 52M | |||||
Cash from Investing | -538M | -1.06B | -2.3B | -21.35B | -4.13B | |||||
Short Term Debt Issued, Total | - | 194M | - | 3.09B | 25M | |||||
Long-Term Debt Issued, Total | - | 5.93B | 4.46B | 12.88B | 5.74B | |||||
Total Debt Issued | - | 6.12B | 4.46B | 15.97B | 5.76B | |||||
Short Term Debt Repaid, Total | -160M | - | -120M | -3B | - | |||||
Long-Term Debt Repaid, Total | -6.02B | -11.43B | -3.88B | -2.87B | -10.94B | |||||
Total Debt Repaid | -6.18B | -11.43B | -4B | -5.87B | -10.94B | |||||
Issuance of Common Stock | - | - | - | - | - | |||||
Repurchase of Common Stock | -6.29B | -8B | -5.16B | - | - | |||||
Common Dividends Paid | -4.4B | -4.63B | -4.74B | -4.86B | -5.04B | |||||
Common & Preferred Stock Dividends Paid | -4.4B | -4.63B | -4.74B | -4.86B | -5.04B | |||||
Other Financing Activities, Total | 641M | 984M | 27M | -106M | -128M | |||||
Cash from Financing | -16.22B | -16.96B | -9.42B | 5.13B | -10.35B | |||||
Foreign Exchange Rate Adjustments | -102M | -33M | 45M | -137M | 195M | |||||
Net Change in Cash | -657M | -4.99B | 2.19B | -1.17B | -129M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 1.5B | 1.4B | 1.2B | 1.8B | 2.1B | |||||
Cash Income Tax Paid (Refund) | 3.5B | 5.4B | 4.3B | 3.9B | 3.26B | |||||
Levered Free Cash Flow | 13.57B | 13.83B | 13.78B | 16.89B | 11.15B | |||||
Unlevered Free Cash Flow | 14.38B | 14.56B | 14.51B | 18.11B | 12.33B | |||||
Change In Net Working Capital | 2.12B | 1.24B | -21M | -3.14B | 389M | |||||
Net Debt Issued / Repaid | -6.18B | -5.31B | 456M | 10.1B | -5.18B |
Select your edition
All financial news and data tailored to specific country editions
















